减重用司美格鲁肽片上市申请获受理 口服减重药战火燃至中国市场

每日经济新闻
Aug 31

口服减重药物的“战火”正蔓延至中国市场。  据诺和诺德方面消息,8月27日,公司递交的诺和盈片剂(司美格鲁肽片)用于长期体重管理的上市申请,已正式获得受理。在此之前,这款药物已经在美国市场展现出其商业潜力——自2026年1月上市以来,累计处方量迅速突破500万张,仅上半年即贡献销售额8.55亿美元。  作为“老对手”,礼来已于2025年底向中国国家药品监督管理局提交口服小分子GLP-1(胰高血糖素...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10